Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript

Zhiqiang Shu: Great. Thanks. And then maybe just quickly on GADLEN platform, you disclosed, I think consistent with last time that you have two preclinical assay. Can you talk about sort of the prioritization there and when we can see more data or more development from those two programs?

Taylor Schreiber: So the B7-H3 molecule is the one we’re considering for development in oncology and the CD20 is the one that we’re considering for development in antibody-mediated autoimmune disease. And what we’re seeking to achieve with the initial clinical study with the GADLEN platform is to select an indication where we believe it will be most likely that a GADLEN molecule will differentiate from CD3-based T cell engagers, antigen-specific antibody molecules and we’ve learned a lot about what Gamma Delta T Cells rely upon to be fully activated. And just like alpha beta T cells, they require a T cell receptor stimulus, which comes from the GADLEN molecule itself and the butyrophilin heterodimer. And they also require a co-stimulatory ligands to be expressed by their target cell.

And so a part of the exercise that is guiding the effort is looking at tumors that express B7-H3 and trying to assure that patients that we might enroll early in a Phase 1 dose escalation study are likely to express those signal to ligands on their tumor. And that’s on the tumor side and on the autoimmune side, you can have certainty actually that any B-cell, which expresses CD20 will also express a signal to ligand in the form of CD80 or 86. And so those are some of the design principles that we have in mind for that Phase 1 trial and we will be providing more specific guidance as to exactly what that study is going to look like in the short-term this year.

Zhiqiang Shu: Great. Thanks, Taylor.

Taylor Schreiber: Thank you.

Operator: Thank you. This concludes the Q&A session of the call. At this time, I would like to turn the call back over to Taylor Schreiber, Chief Executive Officer of Shattuck Labs for closing remarks.

Taylor Schreiber: Thank you, operator and thank you all for joining the Shattuck fourth quarter and full year 2022 financial results and business update conference call. We appreciate your continued interest in Shattuck and we look forward to updating you on our milestones throughout the remainder of what we hope to be an exciting 2023. Thank you.

Operator: Thank you. Again, ladies and gentlemen, that will conclude today’s conference call. We just like to thank you all so much for joining us and wish you all a great remainder of your day. Bye-bye.